Ipca Laboratories Ltd News

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Ipca Labs Q2 results: PAT rises 58% to Rs 229 cr, revenue at Rs 2,355 cr

Ipca Laboratories on Thursday said its consolidated net profit declined 58 per cent year-on-year to Rs 229 crore in the September quarter. The drug firm had reported a net profit of Rs 145 crore in the year-ago period. Revenue from operations rose to Rs 2,355 crore for the second quarter of the current fiscal year as compared with Rs 2,034 crore in the year-ago period, Ipca Laboratories said in a regulatory filing. The company said its domestic formulations business revenue stood at Rs 940 crore for the quarter, up 11 per cent from Rs 845 crore a year earlier. Export of generics stood at Rs 286 crore in the July-September period as against Rs 264 crore, registering a year-on-year growth of 8 per cent. The company said its board has approved an interim dividend of Rs 21 per share of Re 1 each for 2024-25. Shares of the company on Thursday ended 2.02 per cent up at Rs 1,538.65 apiece on the BSE.

Ipca Labs share price hits new high; Motilal Oswal upgrades stock to 'buy'

Ipca Labs news today: In the past one week, the stock of the pharmaceutical company has rallied 14 per cent as compared to 0.16 per cent decline in the BSE Sensex

RBI Policy: Will Bank Nifty fall to 50K or hit 52K today? Key levels here

Derivatives market update Oct 09: NSE F&O data shows that retail investors' are most bullish since the Lok Sabha poll outcome in June; their long-short ratio in index futures rose to 1.44.

Trent, Dixon, Ipca, Coforge, Akzo Nobel hit record highs; rally up to 8%

In Q2FY25, Dixon Technologies; revenue may rise 91 per cent Y-o-Y on robust growth in mobiles & new acquisition, according to analysts at Elara Capital

F&O Insights: Will Bank Nifty see short-covering? Check key levels here

Derivatives market update for Sept 11: Bank Nifty weekly options PCR stands at 0.9:1; key trigger point at 51,550. Premium in Bank Nifty futures down to 99 pts from 255 pts in just 3 trading sessions.

F&O Cues: Premium jumps in Nifty, Bank Nifty futures; options flag caution

Derivatives market update for Sept 06: The Nifty PCR dipped from 0.74, while Bank Nifty to 0.78; reflecting a cautionary trend said Dhupesh Dhameja of SAMCO Securities. Max Financial see short buildup

F&O Insights: IPCA, Divis Lab see bullish bets; 24,700 the key for Nifty

Derivatives market update: 12 stocks including Balrampur Chini, GNFC, India Cement, LIC Housing and National are in F&O ban on Thursday; 2 stocks see buildup up short positions; details here

BSE Healthcare hits new high; rallies 10% in 1 month on strong outlook

Solara Active Pharma Sciences, Indoco Remedies, Dishman Carbogen Amcis, Krishna Institute of Medical Sciences, Divi's Lab, Strides Pharma, Narayana Hrudayalaya and Vijaya Diagnostic were up 5 per cent

IPCA Labs targets Rs 100 crore market with new diabetic foot ulcer drug

This drug has shown a 77.20 per cent ulcer closure rate in clinical trials, offering hope for a condition that often leads to severe outcomes like lower limb amputations

Ipca Labs may outpace past 5-year growth ahead, analysts say buy the dips

Shares of Ipca Labs slipped 2.82 per cent to Rs 1312.55 per share on the BSE in Friday's early morning trade

Ipca Labs Q1 results: Net profit rises 18% to Rs 192 cr, revenue up 32%

The firm's revenue from operations rose to Rs 2,093 crore, a 32 per cent rise from Rs 1,585 crore reported in Q1FY24

Ipca Labs Q1 results: Net profit up 18% at Rs 192 cr on robust sales

Ipca Laboratories on Tuesday said its consolidated net profit increased 18 per cent to Rs 192 crore for the first quarter ended June 30, 2024 aided by robust sales in the domestic market. The drug firm had reported a net profit of Rs 163 crore for the April-June period of last fiscal. Revenue from operations rose to Rs 2,093 crore for the April-June quarter, as compared to Rs 1,585 crore in the year-ago period, Ipca Laboratories said in a regulatory filing. The drug firm said domestic formulations income rose 12 per cent year-on-year to Rs 873 crore in the first quarter. Exports income, however, declined 4 per cent year-on-year to Rs 591 crore during the June quarter, the company said. Shares of Ipca Laboratories on Tuesday closed 1.33 per cent up at Rs 1,400 apiece on the BSE.

EU Court upholds Rs 126 cr fine imposed on Ipca Labs' unit; stock jumps 4%

The uptick in share price came after the company announced that the EU Court upheld Rs 126 crore fine imposed on Ipca Labs' unit, Unichem Laboratories